Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for patients with advanced malignancies, which include both solid tumors and hematological malignancies (cancers that affect the blood, bone marrow, and lymph nodes). The study involves the use of several investigational drugs, including Tislelizumab, Pamiparib, and Ociperlimab. Tislelizumab is administered as a concentrate for solution for infusion, meaning it is given through a vein. Pamiparib is taken orally in capsule form, and Ociperlimab is provided as a solution for infusion.

The purpose of this study is to evaluate the long-term safety of these investigational drugs in patients with advanced cancers. Participants in this study are those who are already part of a related study and continue to benefit from the treatment. The study will monitor the safety of the treatments by observing any side effects, especially those that are serious or affect vital organs like the heart, liver, or brain. The study will also look at overall survival, which is the time from the start of treatment until death from any cause.

During the study, participants will receive the investigational drugs over a period, with the maximum treatment period for some drugs being up to 178 days. The study aims to ensure that the treatments are safe for long-term use and to gather more information on their effects. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after joining a BeiGene-sponsored parent study. Eligibility is confirmed based on the criteria of the parent study.

    A signed informed consent form is required before starting the study treatment.

  2. Step 2

    Initial treatment phase

    The first dose of study treatment is administered within the allowed treatment interruption period from the parent study.

    The treatment involves the use of investigational drugs such as tislelizumab and pamiparib.

  3. Step 3

    Medication administration

    Tislelizumab is given as an intravenous infusion. The frequency and dosage are determined by the study protocol.

    Pamiparib is administered orally in capsule form. The frequency and dosage are specified in the study protocol.

  4. Step 4

    Monitoring and assessments

    Regular monitoring is conducted to assess the safety of the investigational drugs. This includes checking for any adverse effects.

    Assessments focus on the incidence of adverse events, especially those affecting vital organs or leading to changes in medication.

  5. Step 5

    Long-term safety evaluation

    The main objective is to evaluate the long-term safety of the investigational drugs in patients with advanced malignancies.

    Safety is assessed by tracking adverse events and overall survival from the start of treatment in the parent study.

  6. Step 6

    Study completion

    The study is estimated to end by August 31, 2024.

    Completion involves a final assessment of the patient's condition and any long-term effects of the treatment.

Who can join the trial?

7 criteria

  • Currently participating in a BeiGene-sponsored eligible parent study.
  • Meets the treatment criteria specified in the parent study protocol.
  • The study doctor believes the patient will continue to benefit from and tolerate any of the treatments from the parent study.
  • The first dose of study treatment in this study will be received within the allowed break period from the parent study.
  • Female patients who can have children and female partners of non-sterile males must use highly effective birth control methods before starting the study treatment, during the study, and after the last dose of study treatment.
  • Male patients are eligible if they are abstinent, have had a vasectomy, or agree to use contraception during the study and after the last dose of study treatment. Non-sterile males receiving investigational drugs or other treatments that can affect genes must avoid donating sperm during the study and after the last dose of study treatment.
  • A signed informed consent form must be obtained before enrolling in this study and receiving study treatment.

Who cannot join the trial?

4 criteria

  • Patients who have a different type of cancer than the ones being studied, which are **solid tumors** (a mass of tissue that is not liquid) and **hematological malignancies** (cancers that start in blood-forming tissue).
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specific group being studied.
  • Patients who are considered part of a **vulnerable population**, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Tislelizumab

    is a medication used in the trial to help the body's immune system fight cancer. It works by blocking a specific protein that can stop the immune system from attacking cancer cells, allowing the immune system to better target and destroy these cells.

  • Pamiparib

    is another medication involved in the trial, which is used to treat cancer by interfering with the cancer cells' ability to repair their DNA. This can lead to the death of cancer cells and help slow down or stop the growth of tumors.

  • Other Investigational Agents

    are also part of the trial. These are new drugs that are being tested to see how well they work in treating advanced cancers. The specific details of these agents are not provided, but they are being studied to understand their potential benefits and safety in cancer treatment.

What is already known about the treatment

  • Tislelizumab

    Tislelizumab is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating advanced solid tumors and hematological malignancies. It is an investigational drug, meaning it is still under research and not yet widely available in medical practice. Tislelizumab works by blocking a protein called PD-1 on the surface of immune cells, which helps the immune system recognize and attack cancer cells more effectively. It is classified as an immune checkpoint inhibitor, a type of medication that enhances the body's immune response against cancer.

  • Pamiparib

    Pamiparib is taken orally and is also under investigation in clinical trials for its potential use in treating advanced solid tumors and hematological malignancies. As an investigational drug, it is not yet approved for general medical use. Pamiparib functions by inhibiting an enzyme called PARP, which is involved in repairing damaged DNA in cells. By blocking this enzyme, pamiparib can prevent cancer cells from repairing themselves, leading to their death. It is classified as a PARP inhibitor, a class of drugs that target cancer cell DNA repair mechanisms.

Investigated diseases

  • Solid Tumors

    Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. They can occur in various parts of the body, such as the breast, lung, prostate, or colon. These tumors grow as a result of uncontrolled cell division and can invade nearby tissues. Over time, they may spread to other parts of the body through the bloodstream or lymphatic system. The progression of solid tumors can vary greatly depending on the type and location of the tumor. They are typically classified based on the type of cells they originate from, such as carcinomas or sarcomas.

  • Hematological Malignancies

    Hematological malignancies are cancers that begin in the blood-forming tissue, such as the bone marrow, or in the cells of the immune system. These include leukemia, lymphoma, and myeloma, which affect the production and function of blood cells. The disease often leads to the overproduction of abnormal blood cells, which can crowd out normal cells and impair the body's ability to fight infections, carry oxygen, or control bleeding. As the disease progresses, it can spread to other parts of the body, including the lymph nodes, liver, and spleen. The progression and symptoms can vary widely depending on the specific type of hematological malignancy. They are often characterized by symptoms such as fatigue, fever, and frequent infections.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-508883-31-00Protocol codeBGB-A317-290-LTE1Estimated enrolment429 patientsSponsorBeOne Medicines AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).